Valuation: Evotec SE

Market Cap 518M 594M 489M 444M 832M 57B 836M 5.86B 2.26B 28.98B 2.23B 2.18B 93.24B P/E 2026 *
-2.48x
P/E 2027 * -6.77x
Enterprise Value 661M 758M 624M 567M 1.06B 72.72B 1.07B 7.47B 2.88B 36.97B 2.85B 2.78B 119B EV / Sales 2026 *
1.1x
EV / Sales 2027 * 0.94x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day-4.19%
1 week-7.51%
Current month-14.89%
1 month-16.23%
3 months-37.50%
6 months-34.43%
Current year-48.05%
1 week 1.57
Extreme 1.57
1.75
1 month 1.57
Extreme 1.57
1.97
Current year 1.57
Extreme 1.57
3.87
1 year 1.57
Extreme 1.57
4.27
3 years 1.57
Extreme 1.57
12
5 years 1.57
Extreme 1.57
26.57
10 years 1.57
Extreme 1.57
26.57
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 59 10/06/2024
Change 5-day change 1-year change 3-year change Capi.($)
-4.19%-7.51% - - 594M
+0.11%+2.71%+0.33%+28.59% 46.28B
-1.12%+1.78%+40.07%+27.26% 43.85B
-3.04%-6.29%+322.27%+517.36% 40.93B
-0.74%+1.25%+2.32%+67.94% 39.9B
-0.50%+0.67%+11.79%+40.51% 29.5B
-0.46%+4.22%+21.99%+124.21% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.15%+38.93% 15.22B
-3.14%+31.91%-10.60% - 14.05B
Average -1.31%+3.76%+51.29%+120.69% 29.15B
Weighted average by Cap. -1.03%+1.87%+64.69%+130.23%

Financials

2026 *2027 *
Net sales 601M 689M 567M 515M 965M 66.12B 969M 6.8B 2.62B 33.62B 2.59B 2.53B 108B 724M 830M 684M 621M 1.16B 79.68B 1.17B 8.19B 3.16B 40.51B 3.12B 3.05B 130B
Net income -202M -232M -191M -173M -324M -22.23B -326M -2.28B -882M -11.3B -870M -851M -36.36B -48.25M -55.33M -45.56M -41.37M -77.51M -5.31B -77.84M -546M -211M -2.7B -208M -203M -8.69B
Net Debt 143M 164M 135M 122M 229M 15.72B 230M 1.62B 623M 7.99B 615M 602M 25.71B 162M 186M 153M 139M 261M 17.84B 262M 1.83B 708M 9.07B 699M 683M 29.19B
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,461
Date Price Change Volume
18/09/26 $1.600 -4.19% 1,378,543
17/09/26 $1.670 +2.45% 21,495
16/09/26 $1.630 0.00% 24,916
15/09/26 $1.630 -2.98% 102,165
14/09/26 $1.680 -2.89% 37,704
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.914EUR
Average target price
4.586EUR
Spread / Average Target
+57.37%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!